Abstract
From a series of preclinical studies and animal experiments, we have been able to demonstrate that DNA vaccines are a promising tool in strategies for protecting hosts from a variety of infectious diseases. Since the promoter activity of the human cytomegalovirus immediate–early promoter/ enhancer (CMV promoter) is known to be responsive to an elevation in the level of intracellular cAMP, we hypothesized that use of cAMP analogue (8-Bromo adenosine 3′5′-cyclic monophosphate, 8 Br-cAMP) would increase the level of transgene expression supported by the CMV, and enhance the ability of DNA vaccines to evoke an immune response against the transgene product in vivo. To evaluate this hypothesis, immune responses against HIV-1 envelope protein, gp160, an immunogenic HIV-1 component expressed under the control of the CMV promoter, were evaluated in BALB/c mice with or without stimulation by 8 Br-cAMP. DNA vaccine with 8 Br-cAMP was intramuscularly (i.m.) or intranasally (i.n.) administered to BALB/c mice twice on days 0 and 14. Regardless of which route was used, the combination increased the serum IgG antibody (Ab) titer, HIV-1-specific cytotoxic T lymphocyte (CTL) activity and the delayed-type hypersensitivity (DTH) response, compared with the effect of using the vaccine alone. When administered via the i.n. route, the combination also remarkably increased the titer of secretory IgA (sIgA). Moreover, it induced increased production of interferon-γ with reduction in IL-4 synthesis, and decreased the ratio of serum IgG1/IgG2a. However, these enhancements were not observed when 8 Br-cAMP was coadministered with peptide vaccine or protein antigen. These data suggest that 8 Br-cAMP is able to enhance both humoral and cellular immune responses induced by the DNA vaccine. The induction of T helper type 1 (Th1) immunity against HIV-1 was also enhanced by coadministration of 8 Br-cAMP. A CAT assay study demonstrated that the adjuvant effect of 8 Br-cAMP may be due to the activation of the CMV promoter in the DNA vaccine. The virus challenge experiment in a mouse influenza model also proved our hypothesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Donnelly JJ et al. DNA vaccines Annu Rev Immunol 1997 15: 617–648
Boyer J et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination Nature Med 1997 3: 526–532
Manichan E et al. Genetic immunization against herpes simplex virus: protection is mediated by CD4+ T lymphocytes J Immunol 1995 155: 259–265
Lu S et al. Simian immunodeficiency virus DNA vaccine trial in macaques J Virol 1996 70: 3978–3991
Ghiasi H et al. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge Antivir Res 1995 28: 147–157
Okuda K et al. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV-1 env and rev gene products AIDS Res Hum Retrovir 1995 11: 933–943
Xin K-Q et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine Vaccine 1999 17: 858–866
Xin K-Q et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity Clin Immunol 1999 92: 90–96
Xin K-Q et al. Intranasal administration of HIV-1 DNA vaccine with IL-2 expression plasmid enhances cell-mediated immunity against HIV-1 Immunol 1998 94: 438–444
Tsuji T et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing interleukin-12 J Immunol 1997 158: 4008–4013
Lu Y et al. Macrophage inflammatory protein-1α (MIP-1α) expression plasmid enhances the immune response to DNA vaccination against human immunodeficiency virus type 1 Clin Exp Immunol 1999 115: 335–341
Tsuji T et al. HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid DNA vaccine Immunol 1997 90: 1–6
Tsuji T et al. Immunodulatory effects of plasmid expressing B7-2 on human immunodeficiency virus-1 specific cell-mediated immunity induced by plasmid-encoded the viral antigen Eur J Immunol 1997 27: 782–787
Sasaki S et al. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1 Clin Exp Immunol 1998 111: 30–35
Sasaki S et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1 Infect Immun 1997 65: 3520–3528
Ishii N et al. Cationic liposomes are a strong adjuvant for a human immunodeficiency virus type-1 (HIV-1) vaccine candidate constructed with HIV-1 env and rev genes AIDS Res Hum Retrovir 1997 13: 1421–1428
Fickenscher H et al. The role of a repetitive palindromic sequence element in the human cytomegalovirus major immediate–early enhancer J Gen Virol 1989 70: 107–123
Boshart M et al. A very strong enhancer is located upstream of an immediate–early gene of human cytomegalovirus Cell 1985 41: 521–530
Stamminger T, Fickenscher H, Fleckenstein B . Cell-type specific induction of the major immediate–early enhancer of human cytomegalovirus by cyclic AMP J Gen Virol 1990 71: 105–113
Graham B, Wright P . Candidate AIDS vaccines New Engl J Med 1995 333: 1331–1339
Bolognesi DP et al. HIV vaccine development: a progress report Ann Intern Med 1994 8: 603–611
Girard M et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 J Virol 1995 69: 6239–6248
EL-Amed Z et al. Resistance of chimpanzees immunized with recombinant gp120 SF-2 to challenge by HIV-1 SF-2 AIDS 1995 9: 1313–1322
Berman P et al. Protection of MN rgp120-immunized chimpanzees from heterologous infection with a primary isolated of human immunodficiency virus type 1 J Infect Dis 1996 173: 52–59
Connor R et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines J Virol 1998 72: 1552–1576
Fynan EF et al. DNA vaccines: a novel approach to immunization Int J Immunopharmac 1995 17: 79–83
Germain RN . The ins and outs of antigen processing and presentation Nature 1986 322: 687–689
Miedema F, Klein MR . AIDS pathogenesis: a finite immune response to blame? Science 1996 272: 505–506
Haynes BF, Pantaleo G, Fauci AS . Toward an understanding of the correlates of protective immunity to HIV infection Science 1996 271: 324–328
Koup RA et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J Virol 1994 68: 4650–4655
Pantaleo G et al. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV Nature 1994 370: 463–467
Klein MR et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics J Exp Med 1995 181: 1365–1372
Langlade-Demoyen P et al. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients J Clin Invest 1994 93: 1293–1297
Rowland-Jones S et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women Nature Med 1995 1: 59–64
McAnelly L, Zakon HH . Protein kinase A activation increases sodium current magnitude in the electric organ of Sternopygus J Neurosci 1996 16: 4383–4388
Shintani Y, Marunaka Y . Regulation of chloride channel trafficking by cyclic AMP via protein kinase A-independent pathway in A6 renal epithelial cells Biochem Biophys Res Commun 1996 223: 234–239
Gupta MP et al. Sympathetic control of cardiac myosin heavy chain gene expression Mol Cell Biochem 1996 157: 117–124
Cerne R, Rusin KI, Randic M . Enhancement of the N-methyl-D-aspartate response in spinal dorsal horn neurons by cAMP-dependent protein kinase Neurosci Lett 1993 161: 124–128
Bukawa H et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate Nature Med 1995 1: 681–685
Clerici M et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individual J Immunol 1991 146: 2214–2219
Staats FH, Nichols WG, Palker TJ . Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide TSP10MN (A) J Immunol 1996 157: 462–472
Shirai A et al. Individual cells simultaneously produce both IL-4 and IL-6 in vivo Cytokine 1994 6: 329–336
Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein Science 1993 259: 1745–1749
Montgomery DL et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of vectors DNA Cell Biol 1993 12: 777–783
Robinson HL, Hunt LA, Webster RG . Protection against a lethal influenza challenge by immunization with a hemagglutinin-expressing plasmid DNA Vaccine 1993 11: 957–960
Acknowledgements
We are grateful to Ms T Sasaki, A Honsho and T Takeishi for their secretarial assistance. This work was partially supported by a Grant-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan and The Japan Health Sciences Foundation (K-1027).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arai, H., Xin, KQ., Hamajima, K. et al. 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine. Gene Ther 7, 694–702 (2000). https://doi.org/10.1038/sj.gt.3301145
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301145